Related Experiment Video
Updated: Aug 9, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Hyperkalaemia in cyclosporin-treated renal allograft recipients
Insights
Cyclosporine treatment in kidney transplant patients can lead to sustained hyperkalemia and acidosis. This is often caused by impaired aldosterone and renin function, worsened by beta-blockers.
Area of Science:
- Nephrology
- Immunosuppression Pharmacology
Background:
- Cyclosporine is a common immunosuppressant after renal transplantation.
- Hyperkalemia is a potential side effect of immunosuppressive therapy.
Purpose of the Study:
- To investigate the causes of sustained hyperkalemia in renal allograft recipients treated with cyclosporine.
- To identify factors contributing to hyperkalemia and associated metabolic acidosis.
Main Methods:
- Compared serum potassium levels in cyclosporine recipients versus prednisolone and azathioprine recipients.
- Analyzed renal function, acid-base status, and hormonal levels (aldosterone, renin) in hyperkalemic patients.
- Assessed urine pH and the impact of beta-blockers and nephrectomy.
Main Results:
- Significantly higher mean serum potassium levels observed in cyclosporine group for 9 months.
- Seven of 43 cyclosporine patients developed sustained hyperkalemia (6.0-7.1 mmol/l) with hyperchloremic acidosis.
- Hypoaldosteronism, renal tubular defects, and hyporeninemia (potentially due to beta-blockers) were implicated in hyperkalemic patients.
Conclusions:
- Cyclosporine-induced hyperkalemia in renal transplant recipients is linked to impaired potassium and hydrogen ion secretion.
- Hyporeninemia and hypoaldosteronism, potentially exacerbated by beta-blockers, contribute to this condition.
Abstract:
Mean serum potassium levels were significantly higher for 9 months in renal allograft recipients receiving cyclosporin than in those receiving prednisolone and azathioprine. Sustained hyperkalaemia (serum potassium 6.0-7.1 mmol/l) inappropriate for their renal function (glomerular filtration rate 21-36 ml/min) developed in seven of forty-three cyclosporin-treated patients. All seven patients had hyperchloraemic acidosis; four were able to acidify their urine to pH less than or equal to 5.4. Six of the seven patients were hypertensive and receiving beta-blockers; one had had bilateral nephrectomy. Despite hyperkalaemia, plasma aldosterone levels were within the normal range in five patients and raised in two. During moderate sodium restriction, plasma renin activity was low or low-normal in five of the seven patients. In these patients a combination of hypoaldosteronism and renal tubular damage leading to a tubular defect of potassium and hydrogen ion secretion is the apparent cause of the hyperkalaemia and hyperchloraemic acidosis. Hyporeninaemia caused by beta-blockade probably blunts the aldosterone response to hyperkalaemia, thereby worsening it.
Related Concept Videos
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

